Recent news on Erbitux

Callander rallies to help man pay for cancer drugs  -  25 May 2007
The North Bay Nugget,Earlier this year, Callander council passed a resolution stating its wish for the province to fund Reid's treatment of Erbitux.

Doctor hits out at NHS drugs policy  -  25 May 2007
The Northern Echo,Since early April, Mrs Smith, who is blind and a mother of five, has paid nearly £10000 to have Erbitux privately. Dr Fuat, who has worked as an NHS family

Around the Web in 80 Seconds with Wal-Mart, Target, and Jobless Claims  -  25 May 2007
Schaeffers Research,New Erbitux study to steal cancer spotlight: More than thirty years after President Nixon vowed to win the war on cancer, the battle rages on with no victor

New Erbitux study to steal cancer spotlight  -  May 24, 2007
CNNMoney.comThis year, all eyes will be on Bristol-Myers Squibb (down $0.22 to $30.00, Charts, Fortune 500), which produces the cancer blockbuster Erbitux with biotech

Erbitux cancer drug rebuffed again by UK's NICE  -  May 14, 2007
ReutersO: Quote, Profile, Research Erbitux again on Monday, recommending against its use in combination with radiotherapy for patients with head and neck cancer.

Gene Mutation Linked with Poor Response to Erbitux® in Patients ...  -  May 8, 2007
Cancer Consultants (press release),Erbitux is a type of targeted therapy called a monoclonal antibody. It works by binding to a protein receptor located on many cancer cells called the

Erbitux® Improves Outcomes in Advanced Colorectal Cancer  -  May 3, 2007
Cancer Consultants (press release),Two studies presented at the 2007 annual meeting of the American Association for Cancer Research (AACR) indicate that Erbitux® (cetuximab) improves

Pharma Sector: Few Newsmakers Of The Week - Pharmaxis, Celgene ...  -  May 19, 2007
Trading Markets,Britain's National Institute for Health and Clinical Excellence known as NICE, once again refused to sanction Erbitux on the National Health Service,

Looking Into ImClone's Crystal Ball  -  May 17, 2007
CNBC,ImClone shares Erbitux with Bristol-Myers Squibb. The drug is approved for colon and head and neck cancers, but they're testing it on other tumor types.

ASCO Data Springs More Biotech Leaks  -  May 17, 2007
The Street,I made two phone calls Wednesday morning and was able to obtain specific data contained in the Erbitux abstract, which comes from the so-called Crystal

Head and neck cancer drug not available on NHS  -  May 14, 2007
Earthtimes.orgLONDON - The National Institute for Health and Clinical Excellence (Nice) has decided to reject the drug Erbitux (cetuximab) for people suffering from head

Analysis: Street sees rise in ImClone drug  -  Apr 27, 2007
United Press InternationalImClone's first quarter earnings beat Wall Street's expectations and analysts said the anticipated ramp-up in sales of its cancer drug Erbitux will continue

Analysis: Street sees rise in ImClone drug  -  Apr 27, 2007
United Press InternationalJim Reddoch, an analyst with Friedman, Billings and Ramsey, said the first- quarter numbers gave an indication of the future for Erbitux now that the

ImClone Systems Reports First Quarter 2007 Financial Results  -  Apr 26, 2007
PharmaLive.com (press release),Global net sales of ERBITUX in the first quarter of 2007 were $306.1 million compared to $227.9 million in the first quarter of 2006, an increase of $78.2

Tracking ImClone  -  Apr 27, 2007
Motley FoolSales of Erbitux, ImClone's only marketed product, gained 34% year-over-year this quarter, but revenue was down slightly (once a one-time milestone payment

Investors bet on ImClone drug despite soft quarter  -  Apr 26, 2007
ReutersO: Quote, Profile, Research) reported lower-than-expected first-quarter sales of its cancer drug Erbitux on Thursday, but investors boosted the company's

Experts warn of global gap in cancer treatment  -  May 10, 2007
Scientific AmericanThe biggest differences were seen in four new colorectal and lung cancer drugs - bevacizumab (Avastin); cetuximab (Erbitux); erlotinib (Tarceva); (Alimta);

Experts warn of global gulf in cancer treatment  -  May 9, 2007
Reuters South Africa,The biggest differences were seen in four new colorectal and lung cancer drugs -- Avastin, or bevacizumab; Erbitux, or cetuximab; Tarceva, or erlotinib;

Dying soldier refused life saving drug  -  Apr 27, 2007
Barking and Dagenham Post,Barry Robinson, 60, found out on Friday that a difficult decisions panel decided that the NHS should not pay for a £15000 course of Erbitux - a drug that

UPDATE 3-ImClone profit tops estimates; Erbitux falls short  -  26 Apr 2007
Reuters.uk,..."The results were a little disappointing on the top line; however, we believe US Erbitux sales this quarter are inconsequential to the long-term growth

Bristol-Myers Squibb Company Reports First Quarter 2007 Financial ...  -  26 Apr 2007
PharmaLive.com (press release),The Japanese submission was based on results from studies conducted in Europe and Japan which confirm the activity of ERBITUX® in patients with metastatic

Merck's Erbitux increases survival in metastatic colorectal cancer ...  -  Apr 18, 2007
SpiritIndia,Data presented at this year’s American Association for Cancer Research (AACR) meeting show that Merck KGaA’s targeted cancer therapy Erbitux® (cetuximab)

ERBITUX And Disease Control In Metastatic Colorectal Cancer Patients  -  Apr 17, 2007
eMaxHealth.com,Randomized phase III trial showed ERBITUX significantly improved secondary endpoints of progression-free survival and disease control in metastatic

Researchers link gene mutation to Erbitux response  -  Apr 17, 2007
Scientific AmericanLOS ANGELES (Reuters) - Identifying a gene mutation could reveal which colon cancer patients are likely to benefit from ImClone Systems Inc.'s Erbitux,

Merck KGaA's Erbitux ups survival 50% in colorectal cancer  -  Apr 17, 2007
Pharma Times (subscription),Merck KGaA's targeted cancer therapy Erbitux (cetuximab) has been shown to significantly prolong progression-free survival and increase overall response

Mixed Results in Erbitux Colon Cancer Trial  -  Apr 17, 2007
Cancerpage.com,Researchers said a 1300-patient trial found that a combination of Erbitux, also known as cetuximab, and chemotherapy drug irinotecan significantly improved

Randomized Phase III Trial Showed ERBITUX Significantly Improved ...  -  Apr 16, 2007
Earthtimes.org..."The improvement in progression-free survival and response rate expands our understanding of the significant activity of ERBITUX," said Eric Rowinsky, MD,

Randomized Phase III Trial Showed ERBITUX Significantly Improved ...  -  Apr 16, 2007
PR Newswire (press release),As previously announced, primary endpoint not met; plausibly confounded by survival benefit of post-study treatment with ERBITUX - - Data was presented

Data Available From Erbitux® Phase III Study In First-Line ...  -  Apr 16, 2007
Medical News Today (press release),..."This study was designed to examine the Phase II results we previously observed for ERBITUX in patients with pancreatic cancer," stated Eric K. Rowinsky,

Erbitux Studies Provide Conflicting Data  -  Apr 17, 2007
Dog Flu Diet and Diseases,The results of two clinical trials of Erbitux, which is a new colon cancer drug made by ImClone Systems Inc. are mixed, leaving experts wondering if the

ImClone Systems Cancer Drug ERBITUX Shows Higher Secondary ...  -  Apr 16, 2007
Trading Markets,...(BMY | charts | news | PowerRating) on Monday said results from the EPIC study, which compares ERBITUX or Cetuximab plus chemotherapy drug irinotecan to

Data Still Shows Erbitux Fails Study  -  Apr 16, 2007
Forbes,ImClone Systems Inc. and Bristol-Myers Squibb Co. said Monday results of a late-stage study showed Erbitux and chemotherapy combined failed to meet their

Data still shows Erbitux fails study  -  Apr 16, 2007
Hemscott,NEW YORK (AP) - ImClone Systems Inc. and Bristol-Myers Squibb Co. said Monday results of a late-stage study showed Erbitux and chemotherapy combined failed

Erbitux failed to help pancreatic cancer patients  -  Apr 13, 2007
TopCancerNews.com,ImClone Systems Inc.'s drug Erbitux has failed to help pancreatic cancer patients live longer. It's also failed to grow ImClone's market -- not surprising

Data Available from ERBITUX ® Phase III Study in First-Line ...  -  Apr 10, 2007
Business Wire (press release),...“This study was designed to examine the Phase II results we previously observed for ERBITUX in patients with pancreatic cancer,� stated Eric K. Rowinsky,

ImClone's Erbitux Fails Study in Pancreatic Cancer (Update5)  -  Apr 10, 2007
BloombergApril 10 (Bloomberg) -- ImClone Systems Inc.'s drug Erbitux failed to help pancreatic cancer patients live longer in a study, a setback for the company's

ImClone Systems: Erbitux takes a knock  -  Apr 11, 2007
Pharmaceutical Business ReviewImClone Systems' and Bristol-Myers Squibb's Erbitux in combination with Eli Lilly's Gemzar in patients with locally advanced unresectable or metastatic

Erbitux Misses In Pancreatic Cancer, Dropping ImClone  -  Apr 11, 2007
BioWorld Online,Shares in ImClone Systems Inc. took a 6.4 percent dip on word that Erbitux (cetuximab) missed the primary endpoint in a Phase III pancreatic cancer study,

ImClone's Erbitux flunks new cancer trial  -  Apr 10, 2007
CNNMoney.comBOSTON (Reuters) -- ImClone Systems Inc. said Tuesday that a late-stage trial of its cancer drug Erbitux failed to extend survival in patients with

Erbitux fails pancreatic cancer trial  -  Apr 10, 2007
Canada.com,BOSTON (Reuters) - ImClone Systems Inc. said on Tuesday that a late-stage trial of its cancer drug Erbitux failed to extend survival in patients with

Erbitux Fails to Prolong Life  -  Apr 10, 2007
Wall Street Journal (subscription),Bristol-Myers Squibb Co. and ImClone Systems Inc. said Tuesday their cancer drug Erbitux failed to significantly prolong the lives of people with pancreatic

Biologic Drug Erbitux Proves Disappointing as Treatment for ...  -  Apr 12, 2007
Biologic Drug Report,Biologic drug Erbitux did not "significantly prolong" the lives of pancreatic cancer patients in a new study, ImClone Systems and partner Bristol-Myers

Erbitux fails pancreatic cancer trial  -  Apr 10, 2007
WIS,O) said on Tuesday that a late-stage trial of its cancer drug Erbitux failed to extend survival in patients with pancreatic cancer, sending its shares down

No Survival Benefit with Erbitux in Pancreatic Cancer  -  Apr 11, 2007
Cancerpage.com,BOSTON APR 10, 2007 (Reuters) - ImClone Systems Inc. said on Tuesday that a late-stage trial of Erbitux (cetuximab) failed to extend survival in patients

ImClone shares suffer as Erbitux pancreatic cancer trial fails  -  Apr 11, 2007
Pharma Times (subscription),Days after posting positive data for the drug in head and neck cancer, ImClone Systems has suffered a setback after a late-stage trial of Erbitux in

Amgen On Sale?  -  Apr 24, 2007
Motley FoolSales of Vectibix, on the other hand, appear to be making inroads against similar agents on the market like ImClone's (Nasdaq: IMCL) Erbitux.

ImClone's Erbitux Fails to Extend Life in Pancreatic Cancer  -  Apr 10, 2007
BloombergApril 10 (Bloomberg) -- ImClone Systems Inc. said its Erbitux medicine failed to help pancreatic cancer patients live longer in a study, a setback for the

ImClone's Erbitux Fails Pancreatic Cancer Trial  -  Apr 10, 2007
Reuters.uk,O: Quote, Profile , Research) said on Tuesday that a late-stage trial of its cancer drug Erbitux failed to extend survival in patients with pancreatic

Erbitux fails pancreatic cancer trial  -  Apr 10, 2007
ReutersO: Quote, Profile, Research) said on Tuesday that a late-stage trial of its cancer drug Erbitux failed to improve overall survival in patients with

Erbitux fails pancreatic cancer trial  -  Apr 10, 2007
Reuters.uk,O: Quote, Profile , Research) said on Tuesday that a late-stage trial of its cancer drug Erbitux failed to improve overall survival in patients with

ImClone's Erbitux Fails Study in Pancreatic Cancer (Update2)  -  Apr 10, 2007
BloombergApril 10 (Bloomberg) -- ImClone Systems Inc.'s Erbitux drug failed to help pancreatic cancer patients live longer in a study, a setback for the company's

ImClone Systems, Bristol-Myers Say ERBITUX Phase III Study Fails ...  -  Apr 10, 2007
Trading Markets,...(BMY | charts | news | PowerRating), on Tuesday said that the Phase III study of ERBITUX or Cetuximab plus gemcitabine in patients with locally advanced

Erbitux fails pancreatic cancer trial  -  Apr 10, 2007
Canada.com,BOSTON (Reuters) - ImClone Systems Inc. said on Tuesday that a late-stage trial of its cancer drug Erbitux failed to improve overall survival in patients

ImClone: Erbitux Falls Short on Pancreas  -  Apr 10, 2007
Forbes,Biotech drug maker ImClone Systems Inc. and drug maker Bristol-Myers Squibb Co. said Tuesday a late-stage clinical trial studying Erbitux with chemotherapy

ImClone: Erbitux Falls Short on Pancreas  -  Apr 10, 2007
Houston Chronicle,NEW YORK — Biotech drug maker ImClone Systems Inc. and drug maker Bristol-Myers Squibb Co. said Tuesday a late-stage clinical trial studying Erbitux with

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional